Haldol (Haloperidol) - Summary

HALDOL SUMMARY

HALDOL^® Decanoate 50 (haloperidol)
HALDOL^® Decanoate 100 (haloperidol)
For IM Injection Only

Haloperidol decanoate is the decanoate ester of the butyrophenone, HALDOL (haloperidol). It has a markedly extended duration of effect.

HALDOL Decanoate 50 and HALDOL Decanoate 100 are indicated for the treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy.

See all indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Haldol (Haloperidol)

Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. [2009.07]
Antagonists of the N-methyl-D-aspartate (NMDA) receptors such as ketamine, induce abnormalities in healthy subjects similar to those found in schizophrenia. However, recent evidence, suggests that most of the currently known NMDA antagonists have a broader receptor profile than originally thought...

The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. [2009.06]
OBJECTIVE: The prototypical atypical antipsychotic agent, clozapine, is more efficacious for refractory schizophrenia than the 'typical' antipsychotics, but the mechanism underlying this enhanced efficacy is still under investigation. Since 2002, at least 22 association studies have shown that the DTNBP1 can be associated with the risk for schizophrenia. We hypothesized that DTNBP1 might also influence the response to antipsychotic treatments. This study aimed to investigate the relationship between the DTNBP1 and the effects of clozapine and haloperidol on refractory schizophrenia... CONCLUSION: This study shows that the DTNBP1 gene modulates the effects of both the atypical antipsychotic clozapine and the typical antipsychotic haloperidol. Participants with different DTNBP1 diplotypes, haplotypes, genotypes, or alleles might have different responses to these antipsychotics.

Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. [2009.05.15]
BACKGROUND: One third to two thirds of people with schizophrenia have persistent psychotic symptoms despite clozapine treatment. Under real-world circumstances, the need to provide effective therapeutic interventions to patients who do not have an optimal response to clozapine has been cited as the most common reason for simultaneously prescribing a second antipsychotic drug in combination treatment strategies...

Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. [2009.05]
CONCLUSION: Haloperidol, olanzapine, and risperidone were equally effective in treating cognitive deficits of psychosis. The effect of practice clearly contributes to cognitive score improvements after treatment with antipsychotics. Our results provide important information regarding the practical utility of antipsychotic treatments to improve cognition and could have implications for developing novel approaches for cognitive pharmacotherapy in schizophrenia. Copyright 2009 Physicians Postgraduate Press, Inc.

Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. [2009.05]
CONCLUSIONS: In this prospective randomized trial, clozapine and olanzapine were associated with weight gain. Clozapine was associated with increases in both lipids and glucose. This effect was most prominent in the African-American patients.

more studies >>

Clinical Trials Related to Haldol (Haloperidol)

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients [Terminated]
The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.

Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans [Completed]
We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.

Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia [Completed]
The purpose of this study is to compare intramuscular Olanzapine and intramuscular Haloperidol in changing of agitation in patients with schizophrenia

Haloperidol vs Olanzapine for the Management of ICU Delirium [Recruiting]
The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol is in fact superior to olanzapine in treating ICU acquired delirium and sustaining delirium free time.

IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia [Recruiting]
The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese populations.

more trials >>

PATIENT REVIEWS / RATINGS / COMMENTS

Haldol review by medical professional caring for 23 year old female patient
		Rating
Overall rating:
Effectiveness:		Highly Effective
Side effects:		No Side Effects
		Treatment Info
Condition / reason:		psychotic out nof control patient
Dosage & duration:		5mg taken given on a prn basis for the period of given on a prn basis
Other conditions:		borderline personality disorder
Other drugs taken:		ativan,
		Reported Results
Benefits:		Was able to gain control after receiving the injection form of the medication.Was helpful in decreasing aggitation,psychosis,delusions.At the end of the required time in seclusion and after giving medication time to take effect patient was able to return to facility population without any further problems.Was able to maintain in a calm manner,much less aggitated and was able to meet to staff to discuss delional ideas.
Side effects:		Drownsy but no untoward effects.Patient was able to be put on routine dose of this medication after effectivness of medication was evaluated to help prevent further problems.When routine dosage was begun patient was given routine medications for any side effects.
Comments:		Patient became aggiatated,delusional and psychotic and needed to be medicated for safty of patient and others.Required seclusion for decrease stimuli for mediation to take effect.Patient was medicated and given the quiet of seclusion and was monitored for saftey.At the end of seclusion time was released and placed back into the facility mileu.